Clinical Trial Update: Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of CTP-543 in adults with moderate to severe alopecia areata has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• CTP-543

Snippet

Sponsor: Concert Pharmaceuticals | Conditions: Alopecia Areata | Phase 2 | Status: COMPLETED | Results posted: 2022-07-19